144 related articles for article (PubMed ID: 12087450)
1. Costs and consequences of different chemotherapy regimens in metastatic colorectal cancer.
Hale JP; Cohen DR; Maughan TS; Stephens RJ
Br J Cancer; 2002 Jun; 86(11):1684-90. PubMed ID: 12087450
[TBL] [Abstract][Full Text] [Related]
2. Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial.
Maughan TS; James RD; Kerr DJ; Ledermann JA; McArdle C; Seymour MT; Cohen D; Hopwood P; Johnston C; Stephens RJ;
Lancet; 2002 May; 359(9317):1555-63. PubMed ID: 12047964
[TBL] [Abstract][Full Text] [Related]
3. Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation.
Ward S; Kaltenthaler E; Cowan J; Brewer N
Health Technol Assess; 2003; 7(32):1-93. PubMed ID: 14604497
[TBL] [Abstract][Full Text] [Related]
4. Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens.
Ross P; Heron J; Cunningham D
Eur J Cancer; 1996; 32A Suppl 5():S13-7. PubMed ID: 8958037
[TBL] [Abstract][Full Text] [Related]
5. Costs incurred by patients undergoing advanced colorectal cancer therapy. A comparison of raltitrexed and fluorouracil plus folinic acid.
Sculpher M; Palmer MK; Heyes A
Pharmacoeconomics; 2000 Apr; 17(4):361-70. PubMed ID: 10947491
[TBL] [Abstract][Full Text] [Related]
6. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
[TBL] [Abstract][Full Text] [Related]
7. Patterns, costs and cost-effectiveness of care in a trial of chemotherapy for advanced non-small cell lung cancer.
Billingham LJ; Bathers S; Burton A; Bryan S; Cullen MH
Lung Cancer; 2002 Aug; 37(2):219-25. PubMed ID: 12140146
[TBL] [Abstract][Full Text] [Related]
8. Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer.
Limat S; Bracco-Nolin CH; Legat-Fagnoni C; Chaigneau L; Stein U; Huchet B; Pivot X; Woronoff-Lemsi MC
Eur J Health Econ; 2006 Jun; 7(2):107-13. PubMed ID: 16474968
[TBL] [Abstract][Full Text] [Related]
9. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
Pandor A; Eggington S; Paisley S; Tappenden P; Sutcliffe P
Health Technol Assess; 2006 Nov; 10(41):iii-iv, xi-xiv, 1-185. PubMed ID: 17049138
[TBL] [Abstract][Full Text] [Related]
10. Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU.
Iveson TJ; Hickish T; Schmitt C; Van Cutsem E
Eur J Cancer; 1999 Dec; 35(13):1796-804. PubMed ID: 10673994
[TBL] [Abstract][Full Text] [Related]
11. The cost-effectiveness of testing for hepatitis C in former injecting drug users.
Castelnuovo E; Thompson-Coon J; Pitt M; Cramp M; Siebert U; Price A; Stein K
Health Technol Assess; 2006 Sep; 10(32):iii-iv, ix-xii, 1-93. PubMed ID: 16948891
[TBL] [Abstract][Full Text] [Related]
12. A patient preference study comparing raltitrexed ('Tomudex') and bolus or infusional 5-fluorouracil regimens in advanced colorectal cancer: influence of side-effects and administration attributes.
Young A; Topham C; Moore J; Turner J; Wardle J; Downes M; Evans V; Kay S
Eur J Cancer Care (Engl); 1999 Sep; 8(3):154-61. PubMed ID: 10763646
[TBL] [Abstract][Full Text] [Related]
13. Surgical stabilisation of the spine compared with a programme of intensive rehabilitation for the management of patients with chronic low back pain: cost utility analysis based on a randomised controlled trial.
Rivero-Arias O; Campbell H; Gray A; Fairbank J; Frost H; Wilson-MacDonald J
BMJ; 2005 May; 330(7502):1239. PubMed ID: 15911536
[TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of hospital at home versus hospital care: cost minimisation analysis of data from randomised controlled trial.
Jones J; Wilson A; Parker H; Wynn A; Jagger C; Spiers N; Parker G
BMJ; 1999 Dec; 319(7224):1547-50. PubMed ID: 10591720
[TBL] [Abstract][Full Text] [Related]
15. Displaced intracapsular hip fractures in fit, older people: a randomised comparison of reduction and fixation, bipolar hemiarthroplasty and total hip arthroplasty.
Keating JF; Grant A; Masson M; Scott NW; Forbes JF
Health Technol Assess; 2005 Oct; 9(41):iii-iv, ix-x, 1-65. PubMed ID: 16202351
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of first-line chemotherapies in metastatic colorectal cancer. Results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 randomized trial.
Borget I; Aupérin A; Pignon JP; Abbas M; Bouché O; Mousseau M; Raoul JL; Bedenne L; Cassan P; Clavero-Fabri MC; Stremsdoerfer N; Nasca S; Queuniet AM; Ducreux M;
Oncology; 2006; 71(1-2):40-8. PubMed ID: 17344670
[TBL] [Abstract][Full Text] [Related]
17. United Kingdom back pain exercise and manipulation (UK BEAM) randomised trial: cost effectiveness of physical treatments for back pain in primary care.
UK BEAM Trial Team
BMJ; 2004 Dec; 329(7479):1381. PubMed ID: 15556954
[TBL] [Abstract][Full Text] [Related]
18. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.
Loveman E; Green C; Kirby J; Takeda A; Picot J; Payne E; Clegg A
Health Technol Assess; 2006 Jan; 10(1):iii-iv, ix-xi, 1-160. PubMed ID: 16409879
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of nurse led intermediate care versus standard care for post-acute medical patients: cost minimisation analysis of data from a randomised controlled trial.
Walsh B; Steiner A; Pickering RM; Ward-Basu J
BMJ; 2005 Mar; 330(7493):699. PubMed ID: 15757959
[TBL] [Abstract][Full Text] [Related]
20. Economic evaluation of a general practitioner with special interests led dermatology service in primary care.
Coast J; Noble S; Noble A; Horrocks S; Asim O; Peters TJ; Salisbury C
BMJ; 2005 Dec; 331(7530):1444-9. PubMed ID: 16339217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
